Product Center
2024 National Vaccine and Health Conference
- Categories:Industry news
- Author:
- Origin:
- Time of issue:2024-04-22
- Views:
(Summary description)On April 20-21, the 2024 National Vaccine and Health Conference was held in Xiongan New Area, Hebei Province. Ab&B Bio brought its first product, the quadrivalent influenza virus subunit vaccine (Huierkangxin®, HRK-X®), to the event once again.
2024 National Vaccine and Health Conference
(Summary description)On April 20-21, the 2024 National Vaccine and Health Conference was held in Xiongan New Area, Hebei Province. Ab&B Bio brought its first product, the quadrivalent influenza virus subunit vaccine (Huierkangxin®, HRK-X®), to the event once again.
- Categories:Industry news
- Author:
- Origin:
- Time of issue:2024-04-22 14:06
- Views:
On April 20-21, the 2024 National Vaccine and Health Conference was held in Xiongan New Area, Hebei Province. Ab&B Bio brought its first product, the quadrivalent influenza virus subunit vaccine (Huierkangxin®, HRK-X®), to the event once again.
The theme of this conference was "Standardization • Expansion • Innovation — Promoting the Construction of a Healthy China with High-Quality Immunization Services", focusing on the scientific and practical issues involved in the high-quality development of vaccine immunization services. More than 3,000 experts and scholars from medical and health institutions, scientific research institutes, and colleges and universities nationwide attended the conference in person, while over 20,000 vaccine and health professionals participated online to exchange research results, share practical experiences, and discuss optimization strategies.
The booth, featuring Ab&B Bio’s unique design, attracted numerous experts, academics, media representatives, and industry peers to stop by. Attendees expressed keen interest and high expectations for the quadrivalent influenza virus subunit vaccine!
The company’s senior leaders visited the booth to engage with experts and academics, demonstrating their sincerity and pragmatism in serving attendees from various sectors.
Representatives from the marketing department enthusiastically and professionally addressed inquiries from attendees about the quadrivalent influenza virus subunit vaccine! Using the on-site influenza virus model, they vividly demonstrated the key feature of the subunit influenza vaccine: its exclusive extraction of the effective antigens hemagglutinin (HA) and neuraminidase (NA).
In the report of the sub-venue "Progress and Application of Vaccine Clinical Trials", Director Pan Hongxing, director of the Vaccine Clinical Evaluation Institute of Jiangsu Provincial Center for Disease Control and Prevention, presented on "Progress in Clinical Evaluation of Domestic New Influenza Vaccines" and introduced the relevant progress of the domestic new quadrivalent subunit influenza vaccine from three aspects: the current status of influenza vaccine application in China and the world, the interim safety data of the Phase III clinical study of the domestic new quadrivalent subunit influenza vaccine, and the scientific research project of the National Evaluation Center.
Since its establishment in 2005, Ab&B Bio has been committed to the R&D, production, and sales of innovative human vaccines. HRK-X®, now commercially available, is China’s first quadrivalent subunit influenza vaccine and is registered as a Class 1 preventive biological product. Ab&B Bio actively contributes to vaccine immunization advancements and the construction of a healthy China, while supporting influenza prevention and control efforts to ensure broader access to safer, more efficient influenza vaccines.
Relevant information
-
The Launch Meeting of Phase I/II Clinical Trial for Recombinant Herpes Zoster Vaccine (CHO Cell) was successfully heldRecently, the Phase I/II clinical trial launch meeting for the recombinant herpes zoster vaccine (CHO cell), co-developed by Ab&B Bio-Tech CO., LTD. JS. and Yither Biotech (Shanghai) Co., Ltd., was successfully held in Henan, and the first-in-human (FIH) dosing was successfully completed. - Ab&B Bio and Yither Bio Have Both Obtained Qualification Certification! 12-30
- Kickoff Meeting for Clinical Research on Quadrivalent Influenza Virus Subunit Vaccine in Children with Nephrotic Syndrome Successfully Held 12-25
- IND Application for Influenza Virus Subunit Vaccine (Adjuvanted) Approved 10-30
- The Application for the Marketing of Trivalent Influenza Virus Subunit Vaccine has been Accepted! 10-08
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
